Cleared Traditional

OPHTHALMIC TRIAL LENSES (K930195) - FDA 510(k) Clearance

Class I Ophthalmic device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1994
Decision
357d
Days
Class 1
Risk

K930195 is an FDA 510(k) clearance for the OPHTHALMIC TRIAL LENSES. Classified as Set, Lens, Trial, Ophthalmic (product code HPC), Class I - General Controls.

Submitted by Optimark Accessories and Instruments (Seattle, US). The FDA issued a Cleared decision on January 6, 1994 after a review of 357 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.1405 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Optimark Accessories and Instruments devices

Submission Details

510(k) Number K930195 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 14, 1993
Decision Date January 06, 1994
Days to Decision 357 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
247d slower than avg
Panel avg: 110d · This submission: 357d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HPC Set, Lens, Trial, Ophthalmic
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 886.1405
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.